文献速递临床试验与 GCP

补肾化痰汤联合八段锦治疗多囊卵巢综合征伴胰岛素抵抗(肾虚痰湿证)的疗效:随机对照试验研究方案

Efficacy of Bushen Huatan Decoction combined with Baduanjin in the treatment of polycystic ovary syndrome with insulin resistance (IR-PCOS), kidney deficiency and phlegm dampness: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-11-07

本研究为随机对照试验,纳入190例肾虚痰湿证的多囊卵巢综合征伴胰岛素抵抗(IR-PCOS)患者,随机分为5组:二甲双胍组、补肾化痰汤(BSHTD)组、八段锦组、BSHTD联合二甲双胍组、BSHTD联合八段锦组。每疗程3个月,共2个疗程。主要结局为HOMA-IR变化及OGTT、胰岛素释放试验改善;次要结局包括月经周期、排卵率、临床妊娠率、性激素、FAI、Ferriman-Gallwey评分、BMI及中医证候积分。旨在形成中医-行为干预的替代治疗方案。

要点

  • 补肾化痰汤联合八段锦可能改善IR-PCOS患者的胰岛素抵抗和糖代谢。
  • 主要结局为HOMA-IR变化及OGTT、胰岛素释放试验改善。
  • 试验注册号ChiCTR2100043415,注册日期2021年2月15日。

核心结论

  • 本试验将探讨补肾化痰汤联合八段锦综合干预方案对IR-PCOS患者月经周期调整、胰岛素抵抗改善及糖代谢紊乱纠正的疗效。
  • 预期形成IR-PCOS的中医-行为干预替代治疗,并促进八段锦在生活方式病中的应用。

研究设计与样本

  • 随机对照试验,纳入190例诊断为IR-PCOS的参与者。
  • 参与者随机分配至5组:A组接受二甲双胍;B组接受补肾化痰汤(BSHTD);C组接受八段锦;D组接受BSHTD联合二甲双胍;E组接受BSHTD联合八段锦。
  • 一个疗程持续3个月,共两个疗程。
  • 相关观察指标在基线、治疗过程中及6个月随访时收集,并全程密切监测可能的不良事件。

关键数值与推荐

  • 主要结局:HOMA-IR变化以及口服葡萄糖耐量试验(OGTT)和胰岛素释放试验(INS)的改善。
  • 次要结局:月经周期、排卵率、临床妊娠率、基础血清性激素水平、游离雄激素指数(FAI)、Ferriman-Gallwey评分、体重指数(BMI)及中医证候积分的改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disease in women. Insulin resistance (IR) has emerged as a central contributor to the pathogenesis of this disease. According to traditional Chinese medicine (TCM), kidney deficiency is the main syndrome of PCOS. The deficiency of the kidney cannot vaporize water-dampness, and the retention of water-dampness accumulates into phlegm dampness stagnation, resulting in visceral dysfunction and metabolic disorder. TCM involving syndrome differentiation and treatment is widely used to adjust women's menstrual cycles. Our patented formula Bushen Huatan Decoction (BSHTD) has been proven to be effective in the clinical treatment of IR-PCOS. Baduanjin also plays an important role in improving metabolic syndrome through lifestyle intervention. This study investigates the clinical efficacy of Bushen Huatan Decoction combined with Baduanjin in IR-PCOS, to form a specific TCM-behaviour intervention plan in the treatment of IR-PCOS. METHODS/DESIGN: This is a randomized controlled trial involving 190 participants diagnosed with IR-PCOS. All participants will be randomly allocated into 5 groups: group A will receive metformin; group B, BSHTD; group C, Baduanjin; group D, BSHTD combined with metformin; and group E, BSHTD combined with Baduanjin. One course of treatment lasts 3 months, a total of two courses. The primary outcomes are changes in the homeostatic model assessment of insulin resistance (HOMA-IR) and improvements in the oral glucose tolerance test (OGTT) and insulin-releasing test (INS). The secondary outcomes are improvements in the menstrual cycle, ovulation rate, clinical pregnancy rate, basic serum sex hormone levels, free androgen index (FAI), Ferriman-Gallwey scores, body mass index (BMI) and TCM syndrome scores. The related observation indexes will be collected at baseline, during the process of treatment and at the 6-month follow-up. Simultaneously, close monitoring of possible adverse events will be performed throughout the trial process. DISCUSSION: This trial will investigate the efficacy of the comprehensive intervention program of Bushen Huatan Decoction combined with Baduanjin on the adjustment of the menstrual cycle, improvement of insulin resistance and correction of glucose metabolism disorder in IR-PCOS patients. It is expected to form an alternative treatment of TCM-behaviour intervention therapy for IR-PCOS and promote the Chinese fitness Qigong Baduanjin in the application of lifestyle diseases. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2100043415 . Registered on 15 February 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Qian H, Xu W, Cui L, et al. Efficacy of Bushen Huatan Decoction combined with Baduanjin in the treatment of polycystic ovary syndrome with insulin resistance (IR-PCOS), kidney deficiency and phlegm dampness: study protocol for a randomized controlled trial. Trials. 2021. PMID: 34743745. doi:10.1186/s13063-021-05770-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。